Cereno Scientific signs agreement with Fluidda, to evaluate the impact of its HDAC inhibitor CS1 on reverse remodeling of pulmonary vessels in patients with PAH September 30, 2024
Cell Impact enhances production capacity through an agreement with Andritz Soutec AG September 27, 2024
Canada’s modified rules on Temporary Foreign Worker Program comes into effect today: How does it impact employers and jobseekers? September 26, 2024
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries September 22, 2024
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024 September 22, 2024
